JP7842101B2 - IL-6およびTNF-αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド - Google Patents

IL-6およびTNF-αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Info

Publication number
JP7842101B2
JP7842101B2 JP2023536863A JP2023536863A JP7842101B2 JP 7842101 B2 JP7842101 B2 JP 7842101B2 JP 2023536863 A JP2023536863 A JP 2023536863A JP 2023536863 A JP2023536863 A JP 2023536863A JP 7842101 B2 JP7842101 B2 JP 7842101B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
polypeptide
isvd
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023536863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553694A5 (cg-RX-API-DMAC7.html
JP2023553694A (ja
Inventor
クリスティアン・アスブランド
ナディーン・ビーゼマン
アン・ブリッジ
ジークリット・コルネリス
カレン・ヘイニンク
エリック・ロレーント
ハイディ・ロンメラエール
シャナ・ファン・ズワム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2023553694A publication Critical patent/JP2023553694A/ja
Publication of JP2023553694A5 publication Critical patent/JP2023553694A5/ja
Application granted granted Critical
Publication of JP7842101B2 publication Critical patent/JP7842101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023536863A 2020-12-18 2021-12-17 IL-6およびTNF-αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド Active JP7842101B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20306612.1 2020-12-18
EP20306612 2020-12-18
US202163167925P 2021-03-30 2021-03-30
US63/167,925 2021-03-30
PCT/EP2021/086595 WO2022129572A1 (en) 2020-12-18 2021-12-17 Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha

Publications (3)

Publication Number Publication Date
JP2023553694A JP2023553694A (ja) 2023-12-25
JP2023553694A5 JP2023553694A5 (cg-RX-API-DMAC7.html) 2024-10-25
JP7842101B2 true JP7842101B2 (ja) 2026-04-07

Family

ID=79185795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536863A Active JP7842101B2 (ja) 2020-12-18 2021-12-17 IL-6およびTNF-αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Country Status (5)

Country Link
US (2) US11897951B2 (cg-RX-API-DMAC7.html)
EP (1) EP4263602A1 (cg-RX-API-DMAC7.html)
JP (1) JP7842101B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230123497A (cg-RX-API-DMAC7.html)
WO (1) WO2022129572A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
KR20250039299A (ko) 2023-09-11 2025-03-20 노보 노르디스크 에이/에스 항-il-6 도메인 항체
WO2026047197A1 (en) 2024-08-30 2026-03-05 Sanofi Biotechnology Differential biomarkers for anti-interleukin-6 and anti-tumor necrosis factor-α treatment response in rheumatoid arthritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2015173325A2 (en) 2014-05-16 2015-11-19 Ablynx Nv Improved immunoglobulin variable domains
WO2017068186A1 (en) 2015-10-22 2017-04-27 Ablynx Nv Gitr agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257406B2 (en) 1986-08-06 1998-08-12 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
JP2598666B2 (ja) 1987-10-19 1997-04-09 忠三 岸本 抗ヒトbcdfモノクローナル抗体
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
SG42954A1 (en) 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
JP2898064B2 (ja) 1989-08-03 1999-05-31 忠三 岸本 ヒトgp130蛋白質
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp gp130蛋白質に対するモノクロ−ナル抗体
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
BR9916765A (pt) 1999-01-05 2001-09-25 Unilever Nv Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原-结合蛋白抑制病毒感染
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
ATE440111T1 (de) 1999-11-29 2009-09-15 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
ATE342922T1 (de) 1999-11-29 2006-11-15 Unilever Nv Immobilisierung von proteinen mit hilfe eines polypeptidsegments
ATE428733T1 (de) 2000-03-14 2009-05-15 Unilever Nv Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) 可変領域配列のクローニング方法
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
NO2768984T3 (cg-RX-API-DMAC7.html) * 2015-11-12 2018-06-09
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
WO2018131234A1 (ja) 2017-01-16 2018-07-19 株式会社村田製作所 ピエゾ抵抗素子、力学量検知センサおよびマイクロフォン
EP4442709A3 (en) * 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2015173325A2 (en) 2014-05-16 2015-11-19 Ablynx Nv Improved immunoglobulin variable domains
WO2017068186A1 (en) 2015-10-22 2017-04-27 Ablynx Nv Gitr agonists

Also Published As

Publication number Publication date
KR20230123497A (ko) 2023-08-23
US20220356241A1 (en) 2022-11-10
US11897951B2 (en) 2024-02-13
TW202239763A (zh) 2022-10-16
WO2022129572A1 (en) 2022-06-23
JP2023553694A (ja) 2023-12-25
US20240301049A1 (en) 2024-09-12
EP4263602A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
TWI861302B (zh) 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
CN114981300B (zh) 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
JP7817994B2 (ja) Il-13およびox40lを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
JP7719775B2 (ja) TNFαおよびOX40Lを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
US11897951B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
US10618964B2 (en) Nanobody against IL-6R
CN116615453A (zh) 包含靶向IL-6和TNF-α的免疫球蛋白单可变结构域的多肽
RU2846433C1 (ru) Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на tnfa и ox40l
JP2026513302A (ja) 抗il-25抗体及びその使用方法
HK40121486A (en) Anti-il-25 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260326

R150 Certificate of patent or registration of utility model

Ref document number: 7842101

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150